Log In
BCIQ
Print this Print this
 

MI-463

  Manage Alerts
Collapse Summary General Information
Company Kura Oncology Inc.
DescriptionSmall molecule inhibiting menin-MLL fusion oncogene
Molecular Target Menin-MLL fusion oncogene
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationLeukemia
Indication DetailsTreat leukemia
Regulatory Designation
PartnerUniversity of Michigan

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/22/2014

Undisclosed

0

Undisclosed

Get a free BioCentury trial today